


Claims

1. Use of compounds of the formula (I)



5

in which

R¹ represents (C₅-C₁₅)-alkyl, (C₅-C₁₅)-alkenyl or (CH₂)_nG,

10

in which

G represents cycloalkyl or represents a 5- or 6-membered heterocycle having one or two oxygen atoms,

15

n represents 0 to 4 and

20

alkyl, alkenyl and G are optionally substituted by 1 to 3 substituents, independently of one another selected from the group consisting of halogen, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, nitro, alkyl, alkoxy, alkylthio, carboxyl, alkoxy carbonyl, amino, alkylamino, alkylcarbonylamino and alkylaminocarbonyl,

25

R² represents (C₁-C₈)-alkyl, (CH₂)_mcycloalkyl, (CH₂)_mheterocyclyl, (CH₂)_maryl or (CH₂)_mheteroaryl,

in which

m represents 0 to 4 and

- 140 -

alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted by 1 to 3 substituents, independently of one another selected from the group consisting of halogen, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, nitro, alkyl, alkoxy, alkylthio, 5 alkoxycarbonyl, amino, alkylamino, alkylcarbonylamino, alkylamino-carbonyl, alkylaminosulphonyl and alkylsulphonylamino,

10 R³ represents (CH₂)_ocycloalkyl, (CH₂)_oheterocyclyl, (CH₂)_oaryl or (CH₂)_oheteroaryl,

in which

o represents 0 to 4 and

15 cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted by 1 to 3 substituents, independently of one another selected from the group consisting of halogen, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, nitro, alkyl, alkoxy, alkylthio, hydroxycarbonyl, 20 alkoxycarbonyl, amino, alkylamino, alkylcarbonylamino, alkylamino-carbonyl, alkylaminosulphonyl and alkylsulphonylamino,

R⁴ represents hydrogen, (C₁-C₄)-alkyl, (CH₂)_pcycloalkyl, (CH₂)_pheterocyclyl, (CH₂)_paryl or (CH₂)_pheteroaryl,

25 in which

p represents 0 to 4 and

30 alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted by 1 to 3 substituents, independently of one another selected


- 141 -

from the group consisting of halogen, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, nitro, alkyl, alkoxy, alkylthio, hydroxycarbonyl, alkoxy carbonyl, amino, alkylamino, alkylcarbonylamino, alkylaminocarbonyl, alkylaminosulphonyl and alkylsulphonylamino,

5

and their salts, hydrates, hydrates of the salts and solvates for the production of a medicament for the prophylaxis and/or treatment of urological disorders.

10 2. Use according to Claim 1, wherein compounds of the formula (I)



in which

R^1 represents $(\text{C}_5\text{-C}_{15})\text{-alkyl}$ or $(\text{CH}_2)_n\text{cycloalkyl}$,

15

in which

n represents 0 to 4 and

20 alkyl and cycloalkyl are optionally substituted by 1 to 3 substituents, independently of one another selected from the group consisting of halogen, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, nitro, alkyl, alkoxy, alkylthio, carboxyl, alkoxy carbonyl, alkylcarbonyl-amino and alkylaminocarbonyl,

25

R^2 represents $(\text{C}_1\text{-C}_8)\text{-alkyl}$, $(\text{CH}_2)_m\text{cycloalkyl}$, $(\text{CH}_2)_m\text{heterocyclyl}$, $(\text{CH}_2)_m\text{aryl}$ or $(\text{CH}_2)_m\text{heteroaryl}$,

- 142 -

in which

m represents 0 to 4 and

5 alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted by 1 to 3 substituents, independently of one another selected from the group consisting of halogen, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, nitro, alkyl, alkoxy, alkylthio, alkoxy carbonyl, amino, alkylamino, alkylcarbonylamino, alkylaminocarbonyl, alkylamino-

10 sulphonyl and alkylsulphonylamino,

R³ represents (CH₂)_ocycloalkyl, (CH₂)_oheterocyclyl, (CH₂)_oaryl or (CH₂)_oheteroaryl,

15

in which

o represents 0 to 4 and

20 cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted by 1 to 3 substituents, independently of one another selected from the group consisting of halogen, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, nitro, alkyl, alkoxy, alkylthio, hydroxycarbonyl, alkoxy carbonyl, amino, alkyl-amino, alkylcarbonylamino, alkylaminocarbonyl, alkylamino-

25 sulphonyl and alkylsulphonylamino,

R⁴ represents hydrogen, (C₁-C₄)-alkyl, (CH₂)_pcycloalkyl, (CH₂)_p-heterocyclyl, (CH₂)_paryl or (CH₂)_pheteroaryl,

30

in which

p represents 0 to 4 and

5 alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are
optionally substituted by 1 to 3 substituents, independently of
one another selected from the group consisting of halogen,
hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, nitro,
alkyl, alkoxy, alkylthio, hydroxycarbonyl, alkoxycarbonyl,
amino, alkylamino, alkylcarbonylamino, alkylaminocarbonyl,
10 alkylaminosulphonyl and alkylsulphonylamino,

and their salts, hydrates, hydrates of the salts and solvates.

3. Use according to Claim 1, wherein compounds of the formula (I)

15

in which

20

R¹ represents neopentyl, (bicyclo[2.2.1]heptyl)methyl, cyclohexylmethyl,
cyclobutylmethyl, cyclopentylmethyl, 2,2-dimethyl-1-butyl, 2-ethyl-2-
methyl-1-butyl, (1-methylcyclopentyl)methyl, 1-methylcyclohexyl,
4-hydroxy-2,2-dimethyl-1-butyl or 2,2-dimethyl-1-but-3-enyl,

25

R² represents (C₁-C₄)-alkyl which may be substituted by hydroxyl or
fluorine or represents benzyl which is optionally substituted by 1 or 2
substituents, independently of one another selected from the group
consisting of fluorine, chlorine, bromine, methyl and trifluoromethyl,

30

R³ represents phenyl, pyridyl or pyrimidyl which for their part are
optionally substituted by a substituent selected from the group
consisting of fluorine, chlorine, trifluoromethyl, methyl, ethyl,
methoxy, ethoxy, n-propoxy, isopropoxy, amino, hydroxyl, hydroxy-

- 144 -

carbonyl, (C₁-C₃)-alkylcarbonylamino and mono-(C₁-C₄)-alkylamino-carbonyl,

R⁴ represents hydrogen

5

and their salts, hydrates, hydrates of the salts and solvates.

- 10 4. Use of compounds of the formula (I) as defined in Claim 1, wherein said urological disorder is benign prostatic hyperplasia.
5. Use of compounds of the formula (I) as defined in Claim 1, wherein said urological disorder is overactive bladder.
- 15 6. Medicaments for the treatment of urological disorders comprising an ECE inhibitor.
7. Medicaments according to claim 6, wherein the ECE inhibitor is a compound of the formula (I) as defined in any one of claim 1 to 3.
- 20 8. Method for the treatment and/or prophylaxis of urological disorders in human and/or animal characterised by administering an ECE inhibitor.